ReviewJournal of neurology2026
Migraine: translational challenges, novel therapies and disease modification.
Review in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is the most common neurological disorder, which after stroke confers the greatest neurological disability in the working population. As with other disorders of brain function, pathophysiological processes are more difficult to delineate, notwithstanding the biological complexities and clinical heterogeneity of the disorder. The current review will outline the framework upon which mechanistic pathways have been predicated. It will examine bench to bedside models: what we have learned from those which have been unsuccessful and address those which have borne fruit, presenting the clinical and exploratory insights gained. In the second part the more recent successes in drug therapeutics are summarised, from clinical trials to real world observations and limitations. With this in sight, the third part emphasises the need to reframe goals towards longer-term disease modification, addressing the impact of confounding comorbidities and moving towards a biopsychosocial model of pain.
Indexed as
Identifiers
43024101What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.